CCL5 and neoplasm: For example, CDK4/6i promotes recruitment of T cells into solid tumors by inducing expression of T‐cell chemotactic chemokines, e.g. CXCL10 and C‐C motif chemokine ligand 5 (CCL5), in tumor cells.[23] Furthermore, treating tumor cells with CDK4/6i facilitates their recognition by the immune system via enhancing expression of major histocompatibility complex class I (MHC‐I).[24, 25]